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Abstract
Introduction and objective. The clinical consequences of malnutrition are multi-directional and result in dysfunctions 
of the majority of internal organs and systems. The results of recent studies suggest that a significant role is played by 
malnutrition in pathophysiology of iron homeostasis disorders, but the underlying mechanism is unclear. The study describes 
the potential role of hepcidin and hemojuvelin in the pathogenesis of disorders of iron metabolism during malnutrition.   
State of knowledge. The participation of hepcidin in regulating iron homeostasis encompasses inhibiting the absorption 
of food iron from enterocytes and inhibiting the release of stored iron from the reticuloendothelial system cells. One of the 
factors that increases the post-translational level is the expression of hepcidin is IL-6. In studies focused on malnutrition 
it was observed that in persons with protein and energy deficits the level of proinflammatory cytokine, i.e. interleukin-6, 
in the serum, increased. The involvement of haemojuvelin in the overall iron homeostasis is related with the regulation 
of expression of the hepcidin coding gene on the transcription level. The highest haemojuvelin expression was observed 
in humans in skeletal muscles. Observations and analyses conducted in vivo allowed the conclusion that soluble HJV and 
cell-related haemojuvelin regulate hepcidin expression in response to changes in iron concentration. The research also 
demonstrated that soluble HJV neutralizes the inductive effect of IL-6 action on hepcidin expression.   
Summary. It can be claimed that in persons with protein and/or protein-energetic malnutrition the muscle mass deficit 
may lead to insufficient production of haemojuvelin and sideropenia.
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INTRODUCTION
Malnutrition is defined as pathology resulting from either 
prolonged deficit of energy nutrients and/or microelements 
in one’s diet or recurring infections or chronic diseases [1]. 
Etiology differentiates three types of malnutrition:
1) energetic (marasmus, cachexia), developing due to 
exposure to long-term energy deficit; 
2) protein (kwashiorkor), resulting from insufficient protein 
consumption and/or catabolic stress related with infections 
and extensive traumas;,
3) mixed, i.e. protein energy malnutrition (PEM), most 
frequently observed in a variety of acute or chronic 
diseases [2].
While analyzing the causes of malnutrition, it should be 
borne in mind that especially in hospital patients it is of a 
secondary character and co-exists with many other diseases 
[3]. Reports also refer to cases in which the consequences 
of malnutrition are the initial symptom of another disease. 
Persons with high risk of developing severe malnutrition 
include patients suffering from cancer and gastrointestinal 
diseases, as well as psychological and neurological disorders 
[4, 5]. A high ratio of malnutrition occurrence is also reported 
in patients with hyperthyroidism and in patients suffering 
from post-traumatic stress [4, 5].
The clinical consequences of malnutrition are multi-
directional and result in dysfunctions of the majority of 
internal organs and systems [6]. The clinical picture of 
malnutrition shows skeletal muscle atrophy, proliferation 
of extracellular space with a tendency for the occurrence 
of oedema, immunity decrease, deficient wound healing, 
susceptibility to decubitus ulcers, decrease of physical 
activity, fatigue, apathy and hypothermia [4, 6, 7]. Results 
of research in the literature suggest that a significant role 
is played by malnutrition in the pathophysiology of iron 
homeostasis disorders.
Iron disorders in severe malnutrition. The unquestionable 
relation between malnutrition and iron disorders (manifested 
in microcytic anaemia) seems to be quite well reflected 
in a number of researches conducted among children 
with severe malnutrition [8, 9, 10]. The research show a 
significant increase of ferritin level in the serum of children 
suffering from malnutrition with concurrent iron deficit, 
in comparison to children with sideropenia who are not 
suffering from malnutrition. [8]. Ferritin concentration 
increase was additionally accompanied by a significant 
reduction of transferin concentration and reduced TIBC 
(total iron-binding capacity). The research performed by 
Agarwali et al. [8] support the claim that malnutrition affects 
the development of iron disorders. Researchers showed that 
among such factors as infections, malnutrition, inflammation 
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or proteinuria, malnutrition exerted the biggest influence 
on the reduction of transferin level and total iron-binding 
capacity [8]. Changes in protein plasma profiles probably 
result from the inflammatory process, co-occurring with 
malnutrition, in the course of which – at the expense of 
functionally important proteins, including transferin – acute 
phase proteins, i.e., ferritin, are synthesized. The results 
of the aforementioned research seem to be particularly 
adverse in view of the research conducted by Broxmeyer 
et al. [11]. The authors research conducted in vitro showed 
the inhibitive influence of ferritin on the proliferation of 
myeloid cells [11]. Six years later, a team led by Vreugdenhil 
proved that removing excessive ferritin from the body by 
using iron chelating substances results in the improvement 
of haematological test results [12].
The fact that malnutrition may play a vital role in the 
pathophysiology of anaemia was also suggested by Mitrache 
et al. who relied on the results of research conducted on 186 
patients with an average age of 85 (between 56–100 years of 
age) [13]. The authors showed in the multi-factor regression 
analysis that anaemia was significantly related with a low 
albumin level in the serum [13]. Other observations made 
in this study addressed the fact that 42% of geriatric patients 
with anaemia also met the criteria for malnutrition.
The role of hepcidin and haemojuvelin in the pathogenesis 
of iron disorders in severe malnutrition. Hepcidin is a 
peptide with high cysteine content and of molecular weight 
of ca. 3 kDa that occurs in body fluids in three forms. In the 
serum, isoforms of 25 and 20 amino acids are identified, 
and a peptide consisting of 25 amino acids is dominant [14]. 
Shorter forms i.e., made of 20 or 22 amino acids are identified 
mostly in urine [14, 15]. The mature and biologically active 
form of hepcidin contains in its sequence 8 cysteine residues 
connected by disulfide bonds [16]; disulfide bonds stabilise 
the cell structure [17]. Results of a number of researches 
focused on hepcidin show that it is a key mediator involved in 
iron homeostasis. The participation of hepcidin in regulating 
the overall iron homeostasis encompasses inhibiting the 
absorption of food iron from the lumen of absorptive 
enterocytes, and inhibiting the release of stored iron from 
the reticuloendothelial system cells. Nemeth et al., using cell 
cultures, showed that hepcidin performs its physiological 
activity through reactions with ferroportin (Fpn), i.e. the 
transmembrane protein receptor [18]. Ferroportin is present 
on the surface of cells, releasing iron to the circulating pool, 
such as absorptive enterocytes, macrophage, hepatocytes, 
and placenta cells [18]. The biological function of ferroportin 
is the transportation of iron from the cell interior to the 
blood vessels. Hepcidin is a factor regulating ferroportin 
expression on the post-translational level [18, 19]. It shows 
the capacity of binding directly with ferroportin molecules; 
hepcidin-Fpn binding is then subject to internalisation. 
Inside the emergent endosome, ferroportin is subject to 
lysosomal degradation. The loss of the cell membrane surface 
ferroportin is a secondary constraint on the process of iron 
release from the cell interior [18, 19].
Regulation of expression of the hepcidin coding gene 
(HAMP), located on the long arm of chromosome 19 (19q13), 
occurs both on the transcription and post-translational level 
[17, 20]. One of the factors with reported influence on hepcidin 
expression on the post-translational level is interleukin 6 
[21–25]. Interleukin-6 induces hepcidin expression, thus 
being a mediator in the development of hypoferremia [23, 
24]. In studies focused on malnutrition it was observed that 
in persons with protein and energy deficits (without any 
infection features) the level of proinflammatory cytokine, 
inter alia interleukin-6, in the serum increases [9, 10, 26]. 
A negative correlation between IL-6 and the condition of 
the muscle mass was also demonstrated [26]. The research 
results presented above also support the claim about the 
essential role of malnutrition in the pathogenesis of iron 
homeostasis disorders.
The involvement of haemojuvelin in the overall iron 
homeostasis is related with the regulation of expression of 
hepcidin coding gene on the transcription level. Activation 
of the hepcidin coding gene on the transcription level occurs 
through two varying cellular signalling pathways: through 
activating Stat3 and through activating Smad proteins 
[20, 27, 28]. Pro-inflammatory cytokines, in particular 
interleukin-6, induce the transcription process of the HAMP 
gene through activating Stat3, and then binding Stat3 to the 
regulatory region in the HAMP promoter [20, 27, 28]. The 
other mechanism of hepcidin expression control depend 
on the BMP/Smad signalling pathway. The connection of 
bone morphogenetic protein (BMP) with type II (BMPR 
II) or type I receptors (BMPR I) (BMP-typeI/typeII) entails 
phosphorylation of RSmad intracellular protein, which is 
then bound with Smad4 (also described as Co-Smad) [20]. 
The emerging complex (RSmad-Smad4) is relocated to the 
nucleus where, interacting with other transcription factors, 
it induces target genes, including the hepcidin gene [20].
The latest research shows a very important role played 
by haemojuvelin (HJV) in regulating the transcription of 
the HAMP gene through the BMP/Smad pathway [29–31]. 
Haemojuvelin is a protein product of the HJV gene located 
on the long arm of chromosome 1 (1q21). The highest 
haemojuvelin expression was observed in humans in skeletal 
muscles, the myocardium, liver, oesophagus and pancreas. 
Initially, researchers proved that in in vitro conditions 
haemojuvelin acts as a co-receptor of bone morphogenetic 
protein which facilitates the activation of the BMP-type I/
type II complex [29]. Subsequent meticulous observations and 
analyses conducted in vivo allowed the conclusion that soluble 
HJV inhibits hepcidin expression [30, 31]. Intraperitoneal 
injection of recombined soluble HJV into mice at the dose 
of 25mg/kg of bodyweight, three times per week for three 
consecutive weeks, resulted in the following: inhibition of 
hepcidin expression, increase in ferroportin expression and 
mobilization of stored iron from the reticuloendothelial 
system cells [30]. The final effect of the activity of exogenous 
soluble HJV was the iron increase in the serum [30].
The authors of the above-mentioned research also 
demonstrated that soluble HJV neutralizes the inductive 
effect of IL-6 action on hepcidin expression. Adding 
interleukin-6 into the hepatic cells (HepG2) culture increased 
hepcidin expression threefold [30]. The already observed and 
stimulating influence of IL-6 on the hepcidin synthesis was 
clearly neutralised when hepatocytes were incubated together 
with IL-6 and in combination with soluble HJV [30]. The 
research performed by Lin et al. demonstrated that soluble 
HJV and cell-related hemojuvelin jointly regulate hepcidin 
expression in response to changes in iron concentration in 
the extracellular space [31]. In view of the aforementioned 
biological activity of haemojuvelin, what seems particularly 
interesting are research results presenting increased release 
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of HJV by skeletal muscle cells in rats in response to iron 
deficits [32]. The authors of these reports suggest that skeletal 
muscles may perform a vital role in iron homeostasis [32]. It 
can be claimed that in persons with protein and/or protein-
energetic malnutrition the muscle mass deficit may lead 
to insufficient production of haemojuvelin, thus yielding a 
secondary result of neutralising physiological response of 
the body to sideropenia.
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